FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1573033539> ?p ?o ?g. }

• W1573033539 abstract "OBJECTIVE: To evaluate physical functioning by level of patient-reported disability in patients with multiple sclerosis (MS) treated with natalizumab in clinical practice. BACKGROUND: Studies have shown natalizumab improves physical aspects of health-related quality of life (HRQoL) in patients with MS as early as 3 months into treatment and can sustain the improvement for 1 year. DESIGN/METHODS: MS patients initiating natalizumab in the United States participated in a longitudinal observational study. The physical component summary (PCS) score of the Short Form -12 (SF-12) provides information on general physical HRQoL. The MS Impact Scale (MSIS-29) physical score is a MS-specific HRQoL measure. Higher PCS scores and lower MSIS-29 physical scores indicate better outcomes. An analysis of covariance was used to evaluate mean scores and changes from baseline (CFB) after controlling for baseline characteristics. Baseline assessments were conducted prior to initiating natalizumab. Scores were stratified by baseline disease step (DS) (DS 0−2 or DS 3−6); DS of 3 indicates the need for walking assistance. RESULTS: A total of 333 patients (78% female; mean age 46.8 years) were evaluated, with 120 patients on natalizumab at 3 years; approximately half were categorized with a baseline DS 0−2 and half with a DS 3−6. Overall, mean PCS scores were 34.06 at baseline and 36.34 at 3 years (CFB 2.81; P =0.0013). Mean PCS scores improved from baseline to 3 years in patients with DS 0−2 (CFB 3.2; P =0.0117) and in patients with DS 3−6 (CFB 1.3; P =0.2447). Overall, mean MSIS-29 physical scores were 47.57 at baseline and 41.90 at 3 years (CFB −7.74; P P =0.0003) and in patients with DS 3−6 (CFB −5.29; P =0.0085). CONCLUSIONS: MS patients treated with natalizumab for 3 years in a clinical practice setting reported improvement in physical aspects of HRQoL. Study Supported by:Biogen Idec Inc. Disclosure: Dr. Vollmer has received personal compensation for activities with Cleveland Clinic, Novartis, Mandell Center for Multiple Sclerosis, Teva Neuroscience, Questcor Pharmaceuticals, Biogen Idec, Xenoport, University of Florida PeerView, and Krog & Partners. Dr. Vollmer has received research support from Biogen Idec, Teva Neuroscience, Genzyme Corp., Ono Pharmaceuticals, Elan Pharmaceuticals, Novartis, Avanir Pharmaceuticals, and Janssen Pharmaceutica. Dr. Foley has received personal compensation for activities with Biogen Idec, Genzyme Corp., and Teva Neuroscience as a consultant. Dr. Foley has received research support from Biogen Idec, Genzyme Corp., Avanir Pharmaceuticals, and Novartis. Dr. Nair has received personal compensation for activities with Janssen Pharmaceuticals Inc, and Biogen Idec as a consultant. Dr. Stephenson has received personal compensation for activities with HealthCore, Inc. as an employee. Dr. Nieckohas has received personal compensation for activities with Biogen Idec as a consultant. Dr. Agarwal has received personal compensation for activities with Biogen Idec as an employee. Dr. Agarwal holds stock and/or stock options in Biogen Idec. Dr. Watson has received personal compensation for activities with Biogen Idec as an employee. Dr. Watson holds stock and/or stock options in Biogen Idec which sponsored research in which Dr. Watson was involved as an investigator." @default.
• W1573033539 created "2016-06-24" @default.
• W1573033539 creator A5000244655 @default.
• W1573033539 creator A5021252267 @default.
• W1573033539 creator A5027116773 @default.
• W1573033539 creator A5046218660 @default.
• W1573033539 creator A5052843779 @default.
• W1573033539 creator A5056278530 @default.
• W1573033539 creator A5066166395 @default.
• W1573033539 date "2014-04-08" @default.
• W1573033539 modified "2023-09-23" @default.
• W1573033539 title "Impact of Natalizumab Treatment for Multiple Sclerosis on Patient-Reported Physical Functioning over 3 Years in US Clinical Practices (P7.210)" @default.
• W1573033539 hasPublicationYear "2014" @default.
• W1573033539 type Work @default.
• W1573033539 sameAs 1573033539 @default.
• W1573033539 citedByCount "0" @default.
• W1573033539 crossrefType "journal-article" @default.
• W1573033539 hasAuthorship W1573033539A5000244655 @default.
• W1573033539 hasAuthorship W1573033539A5021252267 @default.
• W1573033539 hasAuthorship W1573033539A5027116773 @default.
• W1573033539 hasAuthorship W1573033539A5046218660 @default.
• W1573033539 hasAuthorship W1573033539A5052843779 @default.
• W1573033539 hasAuthorship W1573033539A5056278530 @default.
• W1573033539 hasAuthorship W1573033539A5066166395 @default.
• W1573033539 hasConcept C118552586 @default.
• W1573033539 hasConcept C126322002 @default.
• W1573033539 hasConcept C159110408 @default.
• W1573033539 hasConcept C1862650 @default.
• W1573033539 hasConcept C23131810 @default.
• W1573033539 hasConcept C2779625216 @default.
• W1573033539 hasConcept C2779951463 @default.
• W1573033539 hasConcept C2780640218 @default.
• W1573033539 hasConcept C2780892749 @default.
• W1573033539 hasConcept C2781004633 @default.
• W1573033539 hasConcept C71924100 @default.
• W1573033539 hasConceptScore W1573033539C118552586 @default.
• W1573033539 hasConceptScore W1573033539C126322002 @default.
• W1573033539 hasConceptScore W1573033539C159110408 @default.
• W1573033539 hasConceptScore W1573033539C1862650 @default.
• W1573033539 hasConceptScore W1573033539C23131810 @default.
• W1573033539 hasConceptScore W1573033539C2779625216 @default.
• W1573033539 hasConceptScore W1573033539C2779951463 @default.
• W1573033539 hasConceptScore W1573033539C2780640218 @default.
• W1573033539 hasConceptScore W1573033539C2780892749 @default.
• W1573033539 hasConceptScore W1573033539C2781004633 @default.
• W1573033539 hasConceptScore W1573033539C71924100 @default.
• W1573033539 hasOpenAccess W1573033539 @default.
• W1573033539 hasRelatedWork W1485591842 @default.
• W1573033539 hasRelatedWork W1504654674 @default.
• W1573033539 hasRelatedWork W2781904792 @default.
• W1573033539 hasRelatedWork W2800417626 @default.
• W1573033539 hasRelatedWork W2800829679 @default.
• W1573033539 hasRelatedWork W2801940350 @default.
• W1573033539 hasRelatedWork W2803651213 @default.
• W1573033539 hasRelatedWork W2806319173 @default.
• W1573033539 hasRelatedWork W2884571446 @default.
• W1573033539 hasRelatedWork W2885049414 @default.
• W1573033539 hasRelatedWork W2885303563 @default.
• W1573033539 hasRelatedWork W2893281143 @default.
• W1573033539 hasRelatedWork W2938881558 @default.
• W1573033539 hasRelatedWork W2973602172 @default.
• W1573033539 hasRelatedWork W3020380582 @default.
• W1573033539 hasRelatedWork W3139620910 @default.
• W1573033539 hasRelatedWork W3153604484 @default.
• W1573033539 hasRelatedWork W3185129165 @default.
• W1573033539 hasRelatedWork W3211326163 @default.
• W1573033539 hasRelatedWork W2126124709 @default.
• W1573033539 hasVolume "82" @default.
• W1573033539 isParatext "false" @default.
• W1573033539 isRetracted "false" @default.
• W1573033539 magId "1573033539" @default.
• W1573033539 workType "article" @default.